Effect of Blinatumomab vs Chemotherapy on Event-Free Survival in Children With High-Risk First Relapse of B-Cell ALL

This randomized trial compares the effects of blinatumomab, an antibody construct that links CD3+ T cells to CD19+ leukemia cells, vs consolidation chemotherapy as a third consolidation block before allogeneic hematopoietic stem cell transplant (HST) on event-free survival in children with high-risk first-relapse B-cell acute lymphoblastic leukemia (B-ALL).
Source: JAMA - Category: General Medicine Source Type: research